Stanley Laman Group, Ltd. Eagle Pharmaceuticals, Inc. Transaction History
Stanley Laman Group, Ltd.
- $652 Million
- Q4 2024
A detailed history of Stanley Laman Group, Ltd. transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Stanley Laman Group, Ltd. holds 12,000 shares of EGRX stock, worth $14,040. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,000
Previous 12,000
-0.0%
Holding current value
$14,040
Previous $44,000
86.36%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding EGRX
# of Institutions
15Shares Held
498KCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY353KShares$412,7310.0% of portfolio
-
Ajo Vista, LLC Boston, MA56.4KShares$66,0320.92% of portfolio
-
Xtx Topco LTD London, X023.6KShares$27,6040.0% of portfolio
-
Simplex Trading, LLC18.2KShares$21,2490.0% of portfolio
-
Barclays PLC London, X014.2KShares$16,6520.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $15.2M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...